44 results about "Tissue Stains" patented technology

An endoscopic stain is provided that includes a carbon pigment and a suspending / viscosity-increasing agent in a pharmaceutically acceptable delivery vehicle, wherein the carbon pigment has a total level of polycyclic aromatic hydrocarbons (PAH) of not greater than 0.5 ppm. Methods of staining an internal site utilizing the stain of the invention and kits that include the stain of the invention are also provided.

The invention is directed to methods and compositions for deparaffinizing paraffin-embedded biological samples for subsequent tissue staining. The compositions are microemulsions that may include water / oil / surfactant microemulsions, and optionally a cosurfactant. The microemulsions enable deparaffinization without the use of xylene or toluene, and also enable solvent exchange without the use of intermediary alcohol dehydration or alcohol rehydration compositions.

An automated staining system and a reagent container designed for use with the automated staining apparatus. The reagent container includes a reagent containment section capable of containing a volume of a reagent. The reagent containment section includes an upper wall and a base wall that are spaced apart along an axis. The base wall includes a well having a nadir that is aligned axially with an access opening in the upper wall so that a reagent probe entering the opening parallel to said axis will travel toward the nadir. In another aspect of the invention, the reagent container may include a two-dimensional data element containing reagent information. The staining apparatus may include one removable drawer for holding reagent containers and another removable drawer holding slides.

Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.

Provided is a method for highly accurately and quantitatively determining cancer onset or cancer onset risk by quantitative tissue-staining which is conducted in a biotissue with the use of an antibody capable of recognizing a cancer proliferation inhibitor or a cancer metastasis inhibitor, for example, PAR1 antibody inhibiting the mobility and infiltrating properties of cancer cells. Cancer onset or cancer onset risk is determined by a tissue staining method, said method comprising: a step for labeling an antibody, which is capable of recognizing a cancer proliferation inhibitor or a cancer metastasis inhibitor, with a fluorescent substance and then contacting the fluorescent-labeled antibody with a tissue sample; a step for irradiating a tissue site, which has been contacted with said antibody, with an excitation light to give a fluorescence image; a step for acquiring an intrinsic fluorescence image in a neighborhood region on a shorter or longer wavelength side, compared with the region wherein the wavelength of the fluorescence emitted by the fluorescent substance is acquired, in the same visual field at the same focus point as said fluorescence image; a step for conducting an image processing for removing the fluorescent brightness of said intrinsic fluorescence image from the fluorescent brightness of said fluorescence image to give a corrected fluorescence image; a step for counting cells at the tissue site which has been contacted with the antibody; a step for measuring the average fluorescent brightness per fluorescent particle; and a step for calculating the fluorescent particle count per cell.

Provided is a method for determining effectiveness of medicine containing, as components, antibodies that are active components of an antibody preparation such as trastuzumab, or antibodies for a target to a target site of active component, by determining the quantity of the protein recognized by the antibodies with high accuracy, in a quantitative tissue staining method for biological tissue. The effectiveness of the medicine containing antibodies as components is determined by using the tissue staining method including the following steps: a step of labeling the antibodies in a medicine that contains antibodies as components with a fluorescent substance, and bringing the fluorescently labeled antibodies into contact with a tissue sample; a step of irradiating the tissue site contacted with the antibodies with excitation light to obtain a fluorescence image; a step of obtaining an intrinsic fluorescence image in the vicinity of the short-wavelength side or long-wavelength side of the acquisition area of fluorescence wavelength emitted from the fluorescent substance, in the same field of vision and in the same focus as those of the fluorescence image; a step of obtaining a collected fluorescence image by image-processing to eliminate the fluorescent intensity of the intrinsic fluorescence image from the fluorescent intensity of the fluorescence image; a step of counting the number of cells at the tissue site contacted with the antibodies; a step of measuring the average fluorescent intensity of one particle of fluorescent particles; and a step of calculating the number of fluorescent particles per cell.

An embodiment of the method of the invention is a method of automating information flow in a laboratory performing tissue staining comprising positioning a networked label printer adjacent to a cutting station, the printer configured to access patient data directly or indirectly from the hospital LIS, the printer being configured with a data element scanner in electronic communication with said printer; inputting data from a tissue cassette-associated data element at said printer, whereby inputting data comprises reading the data from the cassette-associated data element and uploading the cassette data to the LIS; identifying the corresponding test protocol identifier and then downloading the test protocol data to the printer; printing information on labels corresponding to each test specified in the LIS for the patient; attaching a single label to each slide; and cutting a tissue section for each labeled slide and mounting the section on the slide.

Systems and methods for accelerating tissue processing by treating tissue samples and one or more tissue processing agents with infrasonic vibrations are discussed. Some non-limiting examples of tissue processing agents include a tissue fixative, dehydrating agent, clearing agent, impregnating agent, embedding agent, tissue stain, enzyme, or another chemical that diffuses into the tissue sample when the sample is being preserved or prepared for microscopic examination. The infrasonic vibrations can have a frequency from about 10 to about 600 Hz. The infrasonic vibrations can have an amplitude that is sufficiently high, when combined with the frequency, to induce turbulent mixing of the processing agent and accelerate tissue processing. The tissue sample may optionally be vibrated with ultrasonic vibrations. The ultrasonic vibrations can have a frequency and amplitude that are sufficiently high to induce turbulent mixing of the processing agent and to accelerate tissue processing.

Provided is a method for staining a tissue enabling highly precise staining, by which the expression amount and / or the location of a biological substance in a tissue sample can be detected with a high quantitativity together with detailed information that can be obtained by bright field observation.The tissue staining method of the present invention is a method for staining a tissue, in which both staining that allows bright field observation and fluorescence staining are carried out for the same specific biological substance.

The present invention introduces a radically different way of accelerating biomolecule conjugates into tissue, and hence towards their targets for purposes of tissue staining. The invention provides for an order of magnitude improvement over the prior art diffusion process used to stain tissue. The invention comprises a method of tissue staining by applying an electric field to a tissue sample in the presence of an electrolyte and biomolecular conjugates of interest suspended in the electrolyte. Typical staining times are reduced to seconds as opposed to 30-120 minutes common in the prior art. The invention is also directed to devices for performing the method.

Provided is a tissue staining composition containing carbon particles having a mean particle diameter less than 0.3 μm in diameter (optionally less than 0.2 μm in diameter) together with one or more agents that maintain the carbon particles in suspension (for example, an anti-settling agent and / or surfactant). In certain circumstances, the anti-settling agent may also have mucoadhesive properties. The tissue staining composition is visually dark and does not disperse rapidly when introduced into regions of tissue of interest making it ideal for marking the regions that can be visualized clearly and over prolonged periods of time via, for example, direct visualization, endoscopic or laparoscopic inspection. The invention also provides methods of making and using the tissue staining composition for marking regions of tissue of interest, for example, gastrointestinal tissue, as well as other tissues.

Methods and systems for distinguishing an astrocytic human brain rumor from a non-astrocytic human brain tumor (FIG. 4). In one embodiment a method includes the steps of staining tumor tissue from a subject suspected of having a brain tumor with SR101 and visualizing the tissue stained with SR101 with a fluorescence imaging device to confirm an astrocytic or non-astrocytic tumor type. Advantageously, rumor tissue from a subject is stained ex vivo, and the staining and visualizing steps are performed intraoperatively so as to guide the surgeon and thereby minimize or eliminate the need for a subsequent surgery.